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Abstract 
Background and Aims: Patients with previous colorectal adenomas are at increased risk 
of colorectal cancer. Current guidelines for postpolypectomy surveillance intervals treat 
all tubular adenomas 1 to 9 mm in size with low-grade dysplasia as carrying the same 
level of risk. We evaluated whether 6 to 9 mm adenomas detected at colonoscopy are 
associated with greater risk of advanced neoplasia at follow-up compared with baseline 1 
to 5 mm adenomas.  
Methods: We retrospectively evaluated a colonoscopy database at a single U.S. academic 
center. Patients with baseline examinations demonstrating tubular adenomas 1 to 9 mm in 
size with low-grade dysplasia and no advanced adenomas were included. Follow-up 
colonoscopies were performed at least 200 days later and were assessed for incident 
advanced neoplasia (cancer, high-grade dysplasia, adenoma ≥10 mm in size or villous 
elements).  
Results: There were 2477 qualifying baseline colonoscopies.  The absolute risk of 
metachronous advanced neoplasia increased from 3.6% in patients with 1 to 5 mm 
adenomas to 6.9% in patients with at least one 6 to 9 mm adenoma (p = 0.001). Patients 
with 5 or more adenomas one of which was at least 6 to 9 mm had the highest risk of 
advanced neoplasia at follow-up (10.4%, p = 0.006). When only screening colonoscopies 
were considered, all baseline groups (1-2 adenomas, 3-4 adenomas, ≥ 5 adenomas) with 
adenomas 6 to 9 mm in size had an increased risk for metachronous advanced 
neoplasia(ORs, 4.07; 95% CI, 1.50-11.04; OR, 4.91; 95% CI, 1.44-16.75; OR, 4.71; 95% 
CI, 1.30-17.05, respectively). 
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Conclusions: Patients with baseline small (6-9 mm) adenomas have an elevated risk of 
advanced lesions on follow up compared with patients with only diminutive (1-5 mm) 
adenomas. Postpolypectomy guidelines should consider risk stratification based on small 
versus diminutive adenomas. 
 
 
Introduction 
Patients with previous colorectal adenomas are at increased risk of colorectal cancer, 
though compared with the general population the increased risk may be largely confined 
to those with advanced or multiple (3 or more) adenomas 1-7. In current postpolypectomy 
surveillance guidelines 8, 9, patients are considered at higher risk if they have had an 
advanced conventional adenoma (adenoma ≥10 mm, or with high-grade dysplasia or 
villous elements), or 3 or more adenomas. High-risk patients are recommended to 
undergo their next surveillance colonoscopy at a shorter interval compared with those 
who have only 1 or 2 low risk adenomas (tubular adenomas ≤9 mm in size with only low-
grade dysplasia). 
 
 
ADRs in clinical practice are increasing 10 as a result of increased awareness of the 
importance of quality on prevention of interval cancers 11, 12, the availability of registries 
to facilitate ADR measurements 10, guidelines that endorse measurement of ADR 13, 14, 
and the development of progressively higher-definition colonoscopes as well as add-on 
devices (eg, mucosal exposure devices) 15. As a result, an increasingly large fraction of 
4 
 
screening and surveillance populations have very tiny conventional adenomas detected. 
Patients with even tiny adenomas are assigned to shorter surveillance intervals, which 
results in increased cost, risks, and inconvenience to patients, with perhaps limited 
benefit in cancer protection. Further, the effectiveness of postpolypectomy surveillance is 
limited by marked variability in the quality of performance of the baseline colonoscopy 
13, 14
. Currently, postpolypectomy surveillance guidelines do not account for baseline 
performance or the adenoma detection rate (ADR) of examiners, and generally assume 
that baseline colonoscopy has uniform performance. Future postpolypectomy 
surveillance guidelines might be specified to only apply for doctors with ADRs above a 
certain threshold, or could vary recommended intervals according to ADR. Longer 
surveillance intervals could be particularly appropriate for doctors with high ADRs and 
patients with only tiny adenomas. 
 
 
For these reasons we expect increasing pressure to expand surveillance intervals for 
patients with tiny adenomas. In this regard, in many postpolypectomy surveillance 
observational studies, low-risk adenomas include all tubular adenomas 1 to 9 mm in size 
with only low-grade dysplasia. However, adenoma size is a known predictor of 
subsequent risk, as has been repeatedly shown for adenomas ≥10 mm in size compared 
with 1 to 9 mm in size 1-7. We hypothesized that adenomas 6 to 9 mm in size, often called 
“small adenomas,” could be associated with a greater risk of subsequent development of 
advanced neoplasia compared with diminutive adenomas (defined as 1-5 mm) in size. 
Indeed, though most previous studies have lumped 1 to 5 mm and 6 to 9 mm adenomas 
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together, some studies have suggested that small adenomas are associated with a higher 
risk of subsequent advanced neoplasia than are diminutive adenomas 16, 17. In this report, 
we describe our experience with the risk of subsequent advanced neoplasia in subjects 
with small versus only diminutive conventional adenomas. 
 
Methods 
A database of colonoscopies conducted at a single center (Indiana University Hospital 
and an associated outpatient endoscopy center) from 1999 to 2016 was used. The 
database is periodically updated with procedure information and we have reported 
previously on surveillance findings collected from this database 18. Briefly, the database 
contains patient demographics, polyp findings including histology and size and procedure 
characteristics including indication. Completion of the procedure and bowel preparation 
quality were added to the database in 2012. Permission to review the database for the 
current study was obtained from the Institutional Review Board at Indiana University on 
November 21, 2018. The database at this time consisted of procedures from January 1999 
to June 2016. 
 
We identified patients with only diminutive or small adenomas (<10 mm) and 
categorized them into either having diminutive adenomas or small adenomas and then 
into 6 groups: 1 to 2 adenomas both ≤5 mm, 1 to 2 adenomas with at least one 6 to 9 mm, 
3 to 4 adenomas all ≤5 mm, 3 to 4 adenomas with at least one 6 to 9 mm, 5 or more 
adenomas all ≤5 mm, 5 or more adenomas with at least one 6 to 9 mm. Polyp size was 
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estimated by the endoscopist at the time of the procedure. Patients with concomitant 
serrated lesions at baseline were not excluded. 
We excluded patients with inflammatory bowel disease, colon cancer syndromes 
(familial adenomatous polyposis, hereditary nonpolyposis colorectal cancer, serrated 
polyposis syndrome), advanced adenomas (≥10 mm tubular adenoma, villous component, 
high-grade dysplasia) or cancer at or before the baseline colonoscopy. We only included 
patients who had at least one follow-up examination at our institution at least 200 days 
later than the baseline colonoscopy. 
 
Outcome measures: 
Advanced neoplasia at follow-up was defined as finding a conventional adenoma that 
was 10 mm or larger, had high-grade dysplasia (HGD) or villous elements or cancer. We 
also include sensitivity analyses with an expanded definition of advanced neoplasia 
which considered a sessile serrated polyp (SSP) with cytological dysplasia (CD) or SSP 
≥10 mm along with the abovementioned criteria as definition for advanced neoplasia. We 
also performed subgroup analyses first limiting the sample to screening patients and then 
limiting the sample to patients who had 1 to 2 adenomas with a follow-up interval falling 
between 4.5 to 5.5 years. 
 
Statistical analysis 
We report demographics, interval to follow-up colonoscopy, and advanced neoplasia at 
follow-up for each group. Analysis of variance was used for continuous variables and 
chi-square tests were used for categorical variables. We then assessed the effects of age, 
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gender, bowel preparation quality, indication for baseline colonoscopy, time to follow-up 
and our baseline adenoma categories for risk of advanced neoplasia at follow-up using a 
logistic regression model. We report odds ratios with 95% confidence intervals. All 
analyses were performed with IBM SPSS Statistics, Version 25 (IBM Corp, Armonk, 
NY).  
 
Results 
Among 34,467 patients who underwent procedures from January 1999 to June 2016, we 
identified 2,477 patients who only had diminutive or small adenomas at baseline 
colonoscopy, who never had advanced neoplasia before this examination and also went 
through a follow-up examination at least 200 days later at one of our institutions (Figure 
1). The largest fraction of the baseline cohort had only 1 or 2 diminutive adenomas 
(66%). The absolute risk of advanced neoplasia at follow-up was 3.6% among patients 
with only diminutive adenomas compared with 6.9% among patients with at least one 
small adenoma (71/1,997 vs 33/480, p=0.001) (Table 1). We performed 2 separate 
logistic regression analyses using different adenoma subgroups (Table 2). The first 
logistic regression indicated that age and the presence of a small adenoma were risk 
factors for metachronous advanced neoplasia while gender and time to follow-up 
colonoscopy were not (Table 2). The fraction of baseline bowel preparations that were 
excellent or good was 89.2%. In the multivariable analysis, excellent or good preparation 
at baseline was not associated with advanced neoplasia at follow-up colonoscopy (OR, 
0.65; 95% CI, 0.32-1.31; p=0.229; Table 2).  
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We performed a second logistic regression using more adenoma subgroups (Table 2). In 
the second analysis there was only minimal difference in the results for age, gender, years 
to follow-up, bowel preparation quality or indication from the first analysis, and the 
results are only shown for these factors for the first logistic regression in Table 2. The 
second logistic regression indicated that age (result not shown) and the subcategories of 
patients with at least 3 adenomas one of which was ≥6 mm in size predicted advanced 
neoplasia at follow-up colonoscopy (Table 2). 
 
The absolute risk of metachronous advanced neoplasia was 10.4% (11/106) among 
patients with ≥5 adenomas at least one of which was a small adenoma (Table 3). Patients 
who only had 1 to 2 diminutive adenomas had an absolute risk of 3.3% (54/1625) for 
advanced neoplasia at follow-up.  
 
Sensitivity analysis: 
When SSPs ≥10 mm were also considered as advanced neoplasia, the analysis showed 
similar results (Supplementary Tables 1-4). Similar results were observed when we 
removed 29 patients who had ≥10 adenomas at baseline colonoscopy (Supplementary 
Tables 5-8).      
Tables 4 and 5 show findings at follow-up colonoscopy according to baseline screening 
colonoscopies only. When the analysis was confined to baseline screening examinations 
only, multivariable analyses showed that all subgroups with adenomas 6 to 9 mm had a 
higher incidence of advanced neoplasia at follow-up compared with 1 to 2 adenomas <6 
mm in size, regardless of the number of total adenomas (Table 5).  
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Tables 6 and 7 show an analysis limited to patients with 1 to 2 baseline adenomas and 
who had a follow-up examination between 4.5 and 5.5 years. Patients with a small 
adenoma had a significantly higher risk of advanced neoplasia at follow-up when 
compared with patients with diminutive adenomas only (OR, 5.23; 95% CI, 1.55-17.68).                       
 
Discussion 
In this study we describe a single U.S. center experience of the impact of small versus 
diminutive adenomas at colonoscopy on the risk of advanced neoplasia at follow-up. 
Among patients with ≥5 adenomas, the risk for advanced neoplasia at follow-up was far 
greater for patients who had at least one small adenoma when compared with patients 
with all diminutive adenomas Thus, we found that adenomas in the 6 to 9 mm size range 
increase the risk of subsequent advanced neoplasia compared with persons who have 
diminutive adenomas. Our results suggest that caution is appropriate in lumping all 1 to 9 
mm adenomas together in postpolypectomy surveillance guidelines 9.  
 
In addition to 6 to 9 mm adenomas predicting subsequent advanced neoplasia compared 
with having only diminutive adenomas in our entire study population, we also found that 
the discriminating effect of 6 to 9 mm polyps on subsequent risk of advanced neoplasia 
was present when only baseline colonoscopies performed for screening were considered. 
Thus, when only baseline screening colonoscopies were considered, each of the 3 
subgroups of adenomas organized by number of lesions (1-2 adenomas, 3-4 adenomas, 
and ≥5 adenomas) and containing at least one 6 to 9 mm adenoma had a significantly 
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higher risk of advanced neoplasia at follow-up compared with the subgroup of the same 
number of adenomas composed of only diminutive adenomas. In fact, the predictive 
value of 6 to 9 mm adenomas in screening patients was more striking than the same effect 
for the entire study population. The explanation for this finding is uncertain, but one 
possibility is that patients undergoing baseline surveillance examinations had previous 
examinations at other centers that removed high-risk adenoma findings, but of which we 
were unaware and could not identify from our database. Such patients would remain at 
increased risk of advanced neoplasia despite an intervening surveillance examination at 
our center showing only low-risk adenomas 9. 
 
Most previous studies of risk stratification for subsequent advanced lesions based on 
baseline findings have not stratified lesions 1 to 9 mm in size 1-7. However, 2 small 
studies that did stratify risk by small versus diminutive size of adenomas at baseline 
suggested an increased risk of subsequent advanced lesions in those with small baseline 
adenomas 16, 17. Thus, the observations we made here have been made previously. 
 
During the study interval, endoscopists in our group consistently had ADRs above 
recommended thresholds 19, 20. Because ADRs have been increasing in recent years 10, we 
suspect that our results have good generalizability. Our results may not apply in settings 
where ADRs are low because the absolute risk of advanced neoplasia could be 
substantially higher even in persons with very low-risk findings (because more high-risk 
lesions are missed when ADRs are low). Many of the studies that underlie current 
postpolypectomy surveillance recommendations 10 were performed before the current 
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emphasis on ADRs and before high-definition colonoscopes were available. Thus, the 
prevalence of patients with only tiny adenomas may be substantially different in the 
current study from earlier studies. Indeed, the difference in risk of subsequent advanced 
neoplasia observed in the current study between baseline small versus diminutive 
adenomas groups may largely reflect the current study identifying a large and distinct 
cohort of very low-risk tiny adenomas that were less frequently observed in earlier 
studies. This suggestion warrants additional evaluation.  
 
Limitations of our study include that it is a retrospective analysis of a prospectively 
developed and maintained database. The number of patients in certain of the risk groups 
was small. Nevertheless, the results supporting the predictive value of adenomas in the 6 
to 9 mm size range compared with the 1 to 5 mm size range reached statistical 
significance. ADRs in our unit are likely to be relatively high, which suggests that our 
findings will be increasingly relevant as detection improves in community-based 
colonoscopy. Another potential limitation might be that we did not choose to 
systematically exclude patients with serrated lesions at baseline. Further, we did not 
present data on the impact of concomitant SSPs at baseline, primarily because our 
pathology department has not consistently interpreted SSP versus HP over the study 
interval, as we have twice demonstrated21, 22. Finally, polyp size was estimated 
endoscopically, which may be subject to operator error23, 24 and terminal digit rounding25, 
but these effects are common to postpolypectomy surveillance studies generally. 
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In conclusion, these data indicate that lumping small and diminutive adenomas together in 
postpolypectomy surveillance guidelines may create risk for some patients with 6 to 9 mm 
adenomas and/or increase procedure-related costs and risks for patients with 1 to 5 mm 
adenomas. We recommend that additional groups evaluate the impact of small versus diminutive 
adenomas on the subsequent risk of advanced neoplasia in postpolypectomy surveillance cohorts. 
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Figure 1. Patients excluded from the study 
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Table 1. demographic features and advanced neoplasia at follow-up in patients with diminutive adenomas (1-5 
mm) only and patients with at least one small adenoma (6-9 mm) at baseline colonoscopy 
 Total Patients with 
diminutive 
adenomas only at 
baseline 
colonoscopy 
Patients with at 
least one small 
adenoma at 
baseline 
colonoscopy 
P value 
 
N 2477 1997 480  
Age, years (SD) 58.6 (9.7) 58.3 (9.7) 59.8 (9.5) 0.002 
Male Gender (%) 1382 (55.8) 1083 (54.2) 299 (62.3) 0.001 
Time to follow-
up examination, 
years (SD) 
6 months – 1 
year, n (%) 
1-3 years 
3-5 years 
5+ years 
4.5 (2.4) 
 
 
 
70 (2.8) 
554 (22.4) 
884 (35.7) 
969 (39.1) 
4.6 (2.4) 
 
 
 
49 (2.5) 
413 (20.7) 
675 (33.8) 
860 (43.1) 
3.8 (2.2) 
 
 
 
21 (4.4) 
141 (29.4) 
209 (43.5) 
109 (22.7) 
<0.001 
Excellent or 
good bowel 
preparation†, n 
(%) 
1552 (89.2) 1242 (90.1) 310 (85.6) 0.014 
Indication, n (%) 
Screening 
Surveillance 
Diagnostic 
 
1144 (46.2) 
767 (31) 
566 (22.9) 
 
931 (46.6) 
614 (30.7) 
452 (22.6) 
 
213 (44.4) 
153 (31.9) 
114 (23.8) 
0.673 
Advanced 
neoplasia at 
follow-up, n (%) 
Cancer  
HGD 
VA ≥ 10 mm 
VA< 10 mm 
TA ≥ 10 mm 
104 (4.2) 
 
 
4 (0.2) 
7 (0.3) 
11 (0.4) 
11 (0.4) 
71 (2.9) 
71 (3.6) 
 
 
4 (0.2) 
5 (0.3) 
8 (0.4) 
7 (0.4) 
47 (2.4) 
33 (6.9) 
 
 
- 
2 (0.4) 
3 (0.6) 
4 (0.8) 
24 (5) 
0.001 
 
SD- standard deviation 
HGD – High-grade dysplasia 
VA – Villous or tubulovillous adenoma 
TA – Tubular adenoma 
† Information available for 1740 patients (70.2%) 
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Table 2. Risk factors for advanced neoplasia at follow-up in multivariable analysis§ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Results from the first logistic regression 
**Results from the second logistic regression. Results for age, gender, time to follow-up, bowel preparation 
quality and indication were nearly identical to the first analysis. Therefore, only the results for adenoma 
subgroups are shown for the second analysis 
§ Logistic regression using enter method 
OR – Odds ratio 
 
Factor OR (95% CI) P value 
Age (yearly increment)* 1.05 (1.02-1.08) 0.001 
Gender*  
Female 
Male 
 
1 
0.96 (0.58-1.56) 
 
 
0.854 
Time to follow-up (per year 
increment)* 
1.06 (0.94-1.18) 0.353 
Prep Quality* 
Poor/fair 
Excellent/Good 
 
1 
0.65 (0.32-1.31) 
 
 
0.229 
Indication* 
Screening 
Polyp surveillance 
Diagnostic 
 
1 
1.44 (0.84-2.47) 
0.81 (0.38-1.73) 
 
 
0.185 
0.581 
Baseline adenoma findings* 
All adenomas ≤5 mm 
Any adenoma 6-9 mm 
 
1 
2.29 (1.38-3.80) 
 
 
0.001 
Baseline adenoma findings** 
1-2 adenomas both ≤ 5 mm 
1-2 adenomas one 6-9 mm 
3-4 adenomas all ≤ 5 mm 
3-4 adenomas one 6-9 mm 
≥ 5 adenomas all ≤ 5 mm 
≥ 5 adenomas one 6-9 mm 
 
1 
1.63 (0.78-3.39) 
0.94 (0.41-2.18) 
2.71 (1.14-6.43) 
0.99 (0.29-3.36) 
3.31 (1.51-7.28) 
 
 
0.193 
0.889 
0.024 
0.992 
0.003 
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Table 3. Advanced lesions at follow-up   according to baseline colonoscopy findings 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†Fisher exact test; SD – standard deviation; HGD – High-grade dysplasia; VA – Villous or tubulovillous adenoma; TA – Tubular 
Adenoma 
 
 1-2 both ≤ 5 
mm 
1-2 at least 
one 6-9 mm 
3-4 all ≤ 5 
mm 
3-4 at least 
one 6-9 mm 
5 or more all 
≤ 5 mm 
5 or more at least 
one 6-9 mm 
P value 
N 1625 272 271 102 101 106  
Male, n (%) 854 (53) 156 (57) 159 (59) 64 (63) 70 (69) 79 (75) <0.001 
Age, years (SD) 57.5 (9.7) 58.2 (9.5) 61.2 (8.8) 60.9 (9.7) 61.6 (8.8) 62.9 (9.3) <0.001 
Time to follow-up, years 
(SD) 
6 months – 1 year, n (%) 
1-3 years 
3-5 years 
5+ years 
4.7 (2.4) 
 
43 (2.6) 
321 (19.8) 
506 (31.1) 
755 (46.5) 
4.1 (2.3) 
 
9 (3.3) 
68 (25) 
110 (40.4) 
85 (31.3) 
4.3 (2.2) 
 
4 (1.5) 
56 (20.7) 
121 (44.6) 
90 (33.2) 
3.9 (2.2) 
 
3 (2.9) 
28 (27.5) 
54 (52.9) 
17 (16.7) 
3.5 (1.9) 
 
2 (2) 
36 (35.6) 
48 (47.5) 
15 (14.9) 
2.9 (1.7) 
 
9 (8.5) 
45 (42.5) 
45 (42.5) 
7 (6) 
<0.001 
Excellent/good bowel 
preparation, n (%) 
982 (90) 
 
161 (83) 182 (90.5) 65 (83.3) 78 (90.7) 84 (93.3) 0.019 
Indication at baseline 
colonoscopy, n (%) 
Screening 
Surveillance 
Diagnostic 
 
 
754 (46.4) 
480 (29.5) 
391 (24.1) 
 
 
117 (43) 
79 (29) 
76 (27.9) 
 
 
130 (48) 
95 (35.1) 
46 (17) 
 
 
48 (47.1) 
29 (28.4) 
25 (24.5) 
 
 
47 (46.5) 
39 (38.6) 
15 (14.9) 
 
 
48 (45.3) 
45 (42.5) 
13 (12.3) 
0.003 
Patients with advanced 
neoplasms, n (%) 
54 (3.3) 15 (5.5) 12 (4.4) 7 (6.9) 5 (5) 11 (10.4) 0.006† 
Cancer 
HGD  
VA ≥ 10 mm 
VA < 10 mm 
                          TA ≥ 10 mm 
2 (0.1) 
4 (0.2) 
8 (0.5) 
7 (0.4) 
33 (2) 
0 
1 (0.4) 
2 (0.7) 
1 (0.4) 
11 (4) 
1 (0.4) 
1 (0.4) 
0 
0 
13 (4.8) 
0 
0 
0 
2 (2) 
5 (4.9) 
1 (1) 
0 
0 
0 
4 (4) 
0 
1 (0.9) 
1 (0.9) 
1 (0.9) 
8 (7.5) 
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Table 4. Advanced lesions among 6 baseline groups limited to screening indication only 
 
† Fisher exact 
SD – Standard deviation 
HGD – High-grade dysplasia 
VA – Villous or tubulovillous adenoma 
TA – Tubular adenoma 
 
 Baseline adenoma findings  
 1-2 both ≤ 5 mm 1-2 at least one 
6-9 mm 
3-4 all ≤ 5 mm 3-4 at least one 
6-9 mm 
5 or more all ≤5 
mm 
5 or more at 
least one 6-9 
mm 
P value 
N 754 117 130 48 47 48  
Male, n (%) 416 (55.2) 77 (65.8) 79 (60.8) 32 (66.7) 34 (72.3) 39 (81.3) 0.001 
Age, years (SD) 57.2 (8.2) 57.1 (8.1) 61.4 (7.9) 59.7 (7.9) 60.7 (7.9) 61.7 (7.4) <0.001 
Time to follow-up, 
years (SD) 
6 months-1year, n (%) 
1-3 years 
3-5 years 
5+ years 
5.1 (2.2) 
 
13 (1.7) 
91 (12.1) 
228 (30.2) 
422 (56) 
4.5 (2.0) 
 
5 (4.3) 
15 (12.8) 
50 (42.7) 
47 (40.2) 
4.8 (2.3) 
 
1 (0.8) 
16 (12.3) 
14 (29.2) 
24 (50) 
4.2 (2.4) 
 
- 
14 (29.2) 
24 (50) 
10 (20.8) 
3.6 (1.7) 
 
1 (2.1) 
14 (29.2) 
24 (50) 
10 (20.8) 
3 (1.6) 
 
1 (2.1) 
14 (29.8) 
26 (55.3) 
6 (12.8) 
<0.001 
Excellent/good bowel 
preparation, n (%) 
525 (91) 
 
85 (85.9) 96 (91.4) 35 (85.4) 36 (85.7) 38 (92.7) 0.377† 
Patients with advanced 
neoplasms, n (%) 
12 (1.6) 8 (6.8) 5 (3.8) 4 (8.3) 3 (6.4) 4 (8.3) <0.001† 
Cancer 
HGD  
VA ≥10 mm 
VA <10 mm 
TA ≥10 mm 
- 
2 (0.3) 
- 
2 (0.3) 
8 (1.1) 
- 
1 
- 
1 (0.9) 
6 (5.1) 
- 
- 
- 
- 
5 (3.8) 
- 
- 
- 
- 
4 (8.3) 
1 (2.1) 
- 
- 
- 
2 (4.3) 
- 
- 
- 
- 
4 (8.3) 
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Table 5. Risk factors for advanced neoplasia (screening patients only) in multivariable analysis§ 
 
Factor OR (95% CI) P value 
Age (yearly increment) 1.09 (1.04-1.13) <0.001 
Gender 
Female 
Male 
 
1 
0.89 (0.42-1.92) 
 
 
0.774 
Time to follow-up (per year 
increment) 
1.06 (0.88-1.26) 0.553 
Prep Quality 
Poor/fair 
Excellent/Good 
 
1 
0.62 (0.31-1.27) 
 
 
0.191 
Baseline adenoma findings 
1-2 adenomas both ≤ 5 mm 
1-2 adenomas one 6-9 mm 
3-4 adenomas all ≤ 5 mm 
3-4 adenomas one 6-9 mm 
≥ 5 adenomas all ≤ 5 mm 
≥ 5 adenomas one 6-9 mm 
 
1 
4.07 (1.50-11.04) 
1.12 (0.30-4.19) 
4.91 (1.44-16.75) 
3.24 (0.83-12.62) 
4.71 (1.30-17.05) 
 
 
0.006 
0.861 
0.011 
0.091 
0.018 
§ Logistic regression using enter method 
OR – Odds ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
19 
 
Table 6. Advanced lesions at follow-up according to baseline colonoscopy findings limited to 
patients with 1-2 adenomas at baseline whose follow-up colonoscopy was at 5±0.5 years. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
† Fisher exact 
SD – Standard deviation 
HGD – High-grade dysplasia 
VA – Villous or tubulovillous adenoma 
TA – Tubular adenoma 
 
 
 
 
 
 1-2 both ≤ 5 
mm 
1-2 at least one 
6-9 mm 
P value 
N 461 53  
Male, n (%) 854 (53) 156 (57) <0.001 
Age, y (SD) 58.3 (9.1) 58.7 (9.1) 0.745 
Time to follow-up, 
years (SD) 
3-5 years, n (%) 
5+ years 
5.1 (0.2) 
 
128 (27.8) 
333 (72.2) 
5.0 (0.2) 
 
20 (37.7) 
33 (62.3) 
0.104 
Excellent/good bowel 
preparation, n (%) 
361 (96) 
 
42 (93.3) 0.425† 
Indication at baseline 
colonoscopy, n (%) 
Screening 
Surveillance 
Diagnostic 
 
 
264 (57.3) 
116 (25.2) 
81 (17.6) 
 
 
35 (66) 
10 (18.9) 
8 (15.1) 
0.457 
Patients with advanced 
neoplasms, n (%) 
14 (3) 6 (11.3) 0.011† 
Cancer 
HGD  
VA ≥ 10 mm 
VA < 10 mm 
TA ≥ 10 mm 
1 (0.2) 
2 (0.4) 
1 (0.2) 
3 (0.7) 
7 (1.5) 
- 
1 (1.9) 
1 (1.9) 
- 
4 (7.5) 
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Table 7. Risk factors for advanced neoplasia at follow-up (limited to patients with 1-2 adenomas 
at baseline whose follow-up colonoscopy was at 5±0.5 years) in multivariable analysis§ 
 
Factor OR (95% CI) P value 
Age (yearly increment) 1.06 (0.99-1.13) 0.063 
Gender 
Female 
Male 
 
1 
0.83 (0.26-2.73) 
 
 
0.764 
Time to follow-up (per year  
increment) 
0.25 (0.02-4.07) 0.329 
Prep Quality 
Poor/fair 
Excellent/Good 
 
1 
0.57 (0.06-5.87) 
 
 
0.633 
Indication 
Screening 
Polyp surveillance 
Diagnostic 
 
1 
1.8 (0.53-6.03) 
- 
 
 
0.344 
0.997 
Baseline adenoma findings 
1-2 both ≤5 mm 
1-2 at least one 6-9 mm 
 
1 
5.23 (1.55-17.68) 
 
 
0.008 
 
§ Logistic regression using enter method 
OR – Odds ratio 
 
 
 
 
 
 
 
 
 
 
 
21 
 
Figure legend: 
Figure 1. Patients excluded from the study 
 

Acronyms and abbreviations 
 
 
mm- millimeter 
 
U.S.- United States 
 
ADR- adenoma detection rate 
 
HGD- high grade dysplasia 
 
SSP- sessile serrated polyp 
 
CD- cytological dysplasia 
 
SD – standard deviation 
 
VA – villous or tubulovillous adenoma 
 
TA – tubular adenoma 
 
OR- odds ratio 
 
Supplementary Table 1. Advanced neoplasia according to baseline findings and including sessile serrated 
polyp (SSP) with cytological dysplasia and SSP ≥10 mm as advanced lesions. 
 Patients with 
diminutive adenomas 
(1-5 mm) only 
Patients with at least 
one small adenoma 
(6-9 mm) 
P value 
N 1997 480  
Age, years (SD) 58.3 (9.7) 59.8 (9.5) 0.002 
Male gender (%) 1083 (54.2) 299 (62.3) 0.001 
Time to follow-up examination, 
years (SD) 
6 months – 1 year, no. (%) 
1-3 years 
3-5 years 
5+ years 
4.6 (2.4) 
 
49 (2.5) 
413 (20.7) 
675 (33.8) 
860 (43.1) 
3.8 (2.2) 
 
21 (4.4) 
141 (29.4) 
209 (43.5) 
109 (22.7) 
<0.001 
Excellent or good bowel 
preparation†, n (%) 
1242 (90.1) 310 (85.6) 0.014 
Indication, n (%) 
Screening 
Surveillance 
Diagnostic 
 
931 (46.6) 
614 (30.7) 
452 (22.6) 
 
213 (44.4) 
153 (31.9) 
114 (23.8) 
0.673 
Advanced neoplasia at follow-
up, n (%) 
Cancer 
HGD or SSPCD 
VA ≥10 mm 
VA <10 mm 
TA or SSP ≥10 mm 
92 (4.6) 
 
4 (0.2) 
5 (0.3) 
8 (0.4) 
7 (0.4) 
68 (3.4) 
37 (7.7) 
 
- 
2 (0.4) 
3 (0.6) 
4 (0.8) 
28 (5.8) 
0.006 
 
 
SD – Standard deviation 
HGD – High-grade dysplasia 
VA – Villous or tubulovillous adenoma 
TA – Tubular adenoma 
SSP – Sessile serrated adenoma/polyp 
SSPCD – Sessile serrated polyp with cytological dysplasia 
 
† Bowel preparation quality information available for 1740 of 2477 patients (70.2%) 
Supplementary Table 2. Risk factors for advanced neoplasia according to baseline findings and including 
sessile serrated polyp (SSP) with cytological dysplasia and SSP ≥10 mm as advanced lesions in 
multivariable analysis§ 
 
 
 
 
 
 
 
 
 
 
 
 
 
§ Logistic regression using enter method 
OR – Odds ratio 
Factor OR (95% CI) P value 
Age (yearly increment) 1.04 (1.01-1.06) 0.004 
Gender (male/female) 
Female 
Male 
 
1 
0.79 (0.51-1.21) 
0.281 
Time to follow-up (per year 
increment) 
1.02 (0.92-1.13) 0.756 
Prep Quality 
Poor/fair 
Excellent/Good 
 
1 
0.73 (0.39-1.40) 
0.344 
Indication 
Screening 
Polyp surveillance 
Diagnostic 
 
1 
1.47 (0.91-2.38) 
0.80 (0.41-1.55) 
 
 
0.113 
0.506 
Baseline adenoma findings 
All adenoma ≤5 mm 
Any adenoma  6-9 mm 
 
1 
1.96 (1.24-3.117) 
 
- 
0.004 
Supplementary Table 3. Advanced neoplasia according to baseline findings and including sessile serrated polyp (SSP) with cytological dysplasia 
and SSP ≥10 mm as advanced lesions 
 
SD – Standard deviation 
 Baseline adenoma findings  
 1-2 both less than 
6 mm 
1-2 at least one 6-
9 mm 
3-4 all less than 6 
mm 
3-4 at least one 6-
9 mm 
5 or more all less 
than 6 mm 
5 or more at least 
one 6-9 mm 
P value 
N 1625 272 271 102 101 106  
Male, n (%) 854 (53) 156 (57) 159 (59) 64 (63) 70 (69) 79 (75) <0.001 
Age, years (SD) 57.5 (9.7) 58.2 (9.5) 61.2 (8.8) 60.9 (8.7) 61.6 (8.8) 62.9 (9.3) <0.001 
Time to follow-up, 
years (SD) 
6 months-1year, no. 
(%) 
1-3 years 
3-5 years 
5+ years 
4.7 (2.4) 
 
43 (2.6) 
321 (19.8) 
506 (31.1) 
755 (46.5) 
4.1 (2.3) 
 
9 (3.3) 
68 (25) 
110 (40.4) 
85 (31.3) 
4.3 (2.2) 
 
4 (1.5) 
56 (20.7) 
121 (44.6) 
90 (33.2) 
3.9 (2.2) 
 
3 (2.9) 
28 (27.5) 
54 (52.9) 
17 (16.7) 
3.5 (1.9) 
 
2 (2) 
36 (35.6) 
48 (47.5) 
15 (14.9) 
2.9 (1.7) 
 
9 (8.5) 
45 (42.5) 
45 (42.5) 
7 (6) 
<0.001 
Excellent/good bowel 
preparation, n (%) 
982 (90) 
 
161 (83) 182 (90.5) 65 (83.3) 78 (90.7) 84 (93.3) 0.019 
Indication at baseline 
colonoscopy, n (%) 
Screening 
Surveillance 
Diagnostic 
 
 
754 (46.4) 
480 (29.5) 
391 (24.1) 
 
 
117 (43) 
79 (29) 
76 (27.9) 
 
 
130 (48) 
95 (35.1) 
46 (17) 
 
 
48 (47.1) 
29 (28.4) 
25 (24.5) 
 
 
47 (46.5) 
39 (38.6) 
15 (14.9) 
 
 
48 (45.3) 
45 (42.5) 
13 (12.3) 
0.003 
Patients with advanced 
neoplasms, n (%) 
71 (4.4) 17 (6.3) 15 (5.5) 7 (6.9) 6 (5.9) 13 (12.3) 0.014 
Cancer 
HGD or SSPCD  
VA ≥ 10 mm 
VA < 10 mm 
TA OR SSP ≥ 10 mm 
2 (0.1) 
4 (0.2) 
8 (0.5) 
7 (0.4) 
50 (3.1) 
0 
1 (0.4) 
2 (0.7) 
1 (0.4) 
13 (4.8) 
1 (0.4) 
1 (0.4) 
0 
0 
13 (4.8) 
0 
0 
0 
2 (2) 
5 (4.9) 
1 (1) 
0 
0 
0 
5 (5) 
0 
1 (0.9) 
1 (0.9) 
1 (0.9) 
10 (9.4) 
 
HGD – High grade dysplasia 
SSP – Sessile serrated polyp 
SSPCD – Sessile serrated polyp with cytological dysplasia 
VA – Villous or tubulovillous adenoma 
 
Supplementary Table 4. Risk factors for advanced neoplasia according to baseline findings and including 
sessile serrated adenoma/polyp (SSP) with cytological dysplasia and SSP ≥10 mm as advanced lesions in 
multivariable analysis § 
Factor OR (95% CI) P value 
Age (yearly increment) 1.04 (1.01-1.06) 0.005 
Gender 
Female 
Male 
 
1 
0.78 (0.50-1.20) 
0.254 
Time to follow-up (per year increment) 1.03 (0.92-1.14) 0.633 
Prep Quality 
Poor/fair 
Excellent/Good 
 
1 
0.70 (0.37-1.34) 
 
 
0.282 
Indication 
Screening 
Polyp surveillance 
Diagnostic 
 
1 
1.46 (0.91-2.36) 
0.82 (0.42-1.59) 
 
 
0.121 
0.549 
Baseline adenoma findings 
1-2 adenomas both ≤ 5 mm 
1-2 adenomas with at least one  6-9 mm 
3-4 adenomas all ≤ 5 mm 
3-4 adenomas with at least one  6-9 mm 
≥ 5 adenomas ≤ 5 mm 
≥ 5 adenomas with at least one  6-9 mm 
 
1 
1.44 (0.74-2.78) 
1.01 (0.50-2.06) 
1.99 (0.86-4.62) 
0.72 (0.22-2.41) 
2.97 (1.45-6.08) 
 
- 
0.284 
0.973 
0.110 
0.599 
0.003 
§ Logistic regression using enter method 
 
OR- Odds ratio 
Supplementary Table 5. Advanced neoplasia according to baseline findings after removing 29 patients 
with > 10 adenomas at baseline 
 Patients with 
diminutive adenomas 
(1-5 mm) only  
Patients with at least 
one small adenoma (6-9 
mm) 
P value 
N 1992 456  
Age, years (SD) 58.3 (9.7) 59.6 (9.3) 0.009 
Male gender (%) 1080 (54.2) 280 (61.4) 0.005 
Time to follow-up 
examination, years (SD) 
6 months -1year, n(%) 
1-3 years 
3-5 years 
5+ years 
4.6 (2.4) 
 
48 (2.4) 
409 (20.5) 
675 (33.9) 
860 (43.2) 
3.8 (2.2) 
 
15 (3.3) 
129 (28.3) 
204 (44.7) 
108 (23.7) 
<0.001 
Excellent or good bowel 
preparation, n (%) 
1239 (90.2) 291 (85.1) 0.006 
Indication, n (%) 
Screening 
Surveillance 
Diagnostic 
 
928 (46.6) 
612 (30.7) 
452 (22.7) 
 
205 (45.0) 
141 (30.9) 
110 (24.1) 
0.760 
Advanced neoplasia at 
follow-up (%) 
Cancer 
HGD 
VA ≥ 10 mm 
VA < 10 mm 
TA ≥ 10 mm 
71 (3.6) 
 
4 (0.2) 
5 (0.3) 
8 (0.4) 
7 (0.4) 
47 (2.4 
31 (6.8) 
 
- 
2 (0.4) 
2 (0.4 
4 (0.9 
23 (5) 
0.002 
 
 
SD – Standard deviation 
HGD – High-grade dysplasia 
VA – Villous or tubulovillous adenoma 
TA – Tubular adenoma 
 
Supplementary Table 6. Risk factors for advanced neoplasia according to baseline findings after removing 
29 patients with more than 10 adenomas at baseline in multivariable analysis§ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
§ Logistic regression using enter method 
 
OR – Odds ratio 
Factor OR (95% CI) P value 
Age (yearly increment) 1.05 (1.03-1.08) <0.001 
Gender 
Female 
Male 
 
1 
0.93 (0.57-1.53) 
 
 
0.783 
Time to follow-up (per year 
increment) 
1.06 (0.94-1.18) 0.354 
Prep Quality 
Poor/fair 
Excellent/Good 
 
1 
0.64 (0.31-1.30) 
 
 
0.214 
Indication 
Screening 
Polyp surveillance 
Diagnostic 
 
1 
1.38 (0.80-2.37) 
0.80 (0.37-1.72) 
 
 
0.247 
0.566 
Baseline findings 
All adenomas ≤5  mm 
Any adenoma  6-9 mm 
 
1 
2.34 (1.40-3.91) 
 
- 
0.001 
Supplementary Table 7. Advanced neoplasia according to baseline findings after removing 29 patients with more than 10 adenomas at baseline 
 
 
† Fisher exact 
SD – Standard deviation 
 Baseline adenoma findings  
 1-2 both less than 
6 mm 
1-2 at least one 6-
9 mm 
3-4 all less than 6 
mm 
3-4 at least one 6-
9 mm 
5 or more all less 
than 6 mm 
5 or more at least 
one 6-9 mm 
P value 
N 1625 272 271 102 96 82  
Male, n (%) 854 (53) 156 (57) 159 (59) 64 (63) 67 (70) 60 (73) <0.001 
Age, y (SD) 57.5 (9.7) 58.2 (9.5) 61.2 (8.8) 60.9 (8.7) 61.6 (8.8) 62.9 (9.3) <0.001 
Time to follow-up, 
years (SD) 
6 months-1year, n (%) 
1-3 years 
3-5 years 
5+ years 
4.7 (2.4) 
 
43 (2.6) 
321 (19.8) 
506 (31.1) 
755 (46.5) 
4.1 (2.3) 
 
9 (3.3) 
68 (25) 
110 (40.4) 
85 (31.3) 
4.3 (2.2) 
 
4 (1.5) 
56 (20.7) 
121 (44.6) 
90 (33.2) 
3.9 (2.2) 
 
3 (2.9) 
28 (27.5) 
54 (52.9) 
17 (16.7) 
3.6 (1.9) 
 
1 (1) 
32 (33.3) 
48 (50) 
15 (15.6) 
3.1 (1.8) 
 
3 (3.7) 
33 (40.2) 
40 (48.8) 
6 (7.3) 
<0.001 
Excellent/good bowel 
preparation, n (%) 
982 (90) 
 
161 (83) 182 (90.5) 65 (83.3) 75 (92.6) 65 (92.9) 0.018 
Indication at baseline 
colonoscopy, n (%) 
Screening 
Surveillance 
Diagnostic 
 
 
754 (46.4) 
480 (29.5) 
391 (24.1) 
 
 
117 (43) 
79 (29) 
76 (27.9) 
 
 
130 (48) 
95 (35.1) 
46 (17) 
 
 
48 (47.1) 
29 (28.4) 
25 (24.5) 
 
 
44 (45.8) 
37 (38.5) 
15 (15.6) 
 
 
40 (48.8) 
33 (40.2) 
9 (11) 
0.009 
Patients with advanced 
neoplasms, n (%) 
54 (3.3) 15 (5.5) 12 (4.4) 7 (6.9) 5 (5.2) 9 (11) 0.01† 
Cancer 
HGD  
VA ≥ 10 mm 
VA < 10 mm 
TA ≥ 10 mm 
2 (0.1) 
4 (0.2) 
8 (0.5) 
7 (0.4) 
33 (2) 
0 
1 (0.4) 
2 (0.7) 
1 (0.4) 
11 (4) 
1 (0.4) 
1 (0.4) 
0 
0 
10 (3.7) 
0 
0 
0 
2 (2) 
5 (4.9) 
1 (1) 
0 
0 
0 
4 (4.2) 
0 
1 (0.9) 
0 
1 (1.2) 
7 (8.5) 
 
HGD – High grade dysplasia 
VA – Villous or tubulovillous adenoma 
TA – Tubular adenoma 
Supplementary Table 8. Risk factors for advanced neoplasia according to baseline findings after removing 
29 patients with > 10 adenomas at baseline in multivariable analysis§ 
 
Factor OR (95% CI) P value 
Age (yearly increment) 1.05 (1.02-1.08) <0.001 
Gender 
Female 
Male 
 
1 
0.91 (0.55-1.50) 
 
 
0.705 
Time to follow-up (per year 
increment) 
1.07 (0.95-1.19) 0.269 
Prep Quality 
Poor/fair 
Excellent/Good 
 
1 
0.61 (0.30-1.25) 
 
 
0.174 
Indication 
Screening 
Polyp surveillance 
Diagnostic 
 
1 
1.37 (0.80-2.37) 
0.82 (0.38-1.77) 
 
 
0.255 
0.618 
 Baseline adenoma findings 
1-2 adenomas both ≤ 5 mm 
1-2 adenomas one  6-9 mm 
3-4 adenomas all ≤ 5 mm 
3-4 adenomas one  6-9 mm 
≥ 5 adenomas all ≤ 5 mm 
≥ 5 adenomas one  6-9 mm 
 
1 
1.62 (0.78-3.38) 
0.93 (0.40-2.15) 
2.68 (1.13-6.37) 
1.05 (0.31-3.57) 
3.86 (1.70-8.77) 
 
- 
0.196 
0.864 
0.026 
0.935 
0.001 
§ Logistic regression using enter method 
 
OR – Odds ratio 
